Department of Otolaryngology-Head and Neck Surgery, Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Anticancer Agents Med Chem. 2022;22(6):1080-1090. doi: 10.2174/1871520621666210706101442.
Macrophage migration inhibitory factor (MIF), originally reported as an inflammation regulating molecule, is elevated in various cancer cells, which may promote carcinogenesis. Meanwhile, ISO-1 is a potent small molecular inhibitor of MIF, which has not been investigated in nasopharyngeal carcinoma (NPC), hence the impact of ISO-1 on NPC cells remains to be illustrated.
This study intended to explore the biological function of ISO-1 in NPC cells in vitro and prove a possibility of ISO-1 being a novel agent in NPC treatments.
Gene expression of MIF in Head and Neck squamous cell carcinoma was obtained from The Cancer Genome Atlas (TCGA) database. Nasal pharyngeal tissues were collected from adult patients undergoing nasopharyngeal biopsy for MIF level detection. Proliferation of NPC cell lines 5-8B and 6-10B was studied using Cell Counting Kit-8 (CCK-8) assay and plate-colony-formation assay, apoptosis was determined by flow cytometry and TUNEL staining, migration and invasion capacities were measured by wound-healing assay and transwell assay, all to explore the function of ISO-1 in NPC cells in vitro. Epithelial-to-mesenchymal transition (EMT) level of NPC cells was determined by Western blot analysis and immunofluorescence assay.
Transcript level of MIF was significantly higher in head and neck squamous cell carcinoma. Protein MIF was overexpressed in human NPC tissues compared to non-cancerous ones, and its expression could be compromised by ISO-1 in vitro. 100μM ISO-1 significantly hindered NPC cells' migration and invasion capacitiesin vitro but acted relatively poorly on proliferation and apoptosis. Immunofluorescence assay and Western blotting implied a downregulated EMT level through TGF-β/Smad4 axis in ISO-1 treated NPC cells compared to the vehicle.
This study indicated that MIF antagonist ISO-1 holds an impact on NPC progression by influencing the migration and invasion of NPC cells ISO-1 inhibits the EMT process of NPC cells through TGF-β/Smad4 axis, supporting that prudent application of ISO-1 may be a potential adjuvant treatment for NPC.
巨噬细胞移动抑制因子(MIF)最初被报道为一种炎症调节分子,在各种癌细胞中升高,这可能促进致癌作用。同时,ISO-1 是 MIF 的一种有效的小分子抑制剂,尚未在鼻咽癌(NPC)中进行研究,因此 ISO-1 对 NPC 细胞的影响仍有待阐明。
本研究旨在探讨 ISO-1 在 NPC 细胞中的体外生物学功能,并证明 ISO-1 成为 NPC 治疗的新型药物的可能性。
从癌症基因组图谱(TCGA)数据库中获得 MIF 在头颈部鳞状细胞癌中的基因表达。从接受鼻咽活检的成人患者中收集鼻咽组织以检测 MIF 水平。使用细胞计数试剂盒-8(CCK-8)测定法和平板集落形成测定法研究 NPC 细胞系 5-8B 和 6-10B 的增殖,通过流式细胞术和 TUNEL 染色测定细胞凋亡,通过划痕愈合测定法和 Transwell 测定法测量迁移和侵袭能力,所有这些都旨在探索 ISO-1 在 NPC 细胞中的体外功能。通过 Western blot 分析和免疫荧光测定法确定 NPC 细胞的上皮-间质转化(EMT)水平。
MIF 的转录水平在头颈部鳞状细胞癌中明显更高。与非癌性组织相比,人 NPC 组织中 MIF 蛋白过表达,并且其表达可以通过体外 ISO-1 得到缓解。100μM ISO-1 显著抑制 NPC 细胞的体外迁移和侵袭能力,但对增殖和凋亡的作用相对较差。与载体相比,免疫荧光测定法和 Western blot 表明 ISO-1 处理的 NPC 细胞通过 TGF-β/Smad4 轴下调 EMT 水平。
本研究表明,MIF 拮抗剂 ISO-1 通过影响 NPC 细胞的迁移和侵袭对 NPC 进展产生影响。ISO-1 通过 TGF-β/Smad4 轴抑制 NPC 细胞的 EMT 过程,支持谨慎应用 ISO-1 可能是 NPC 的一种潜在辅助治疗方法。